Clinical Programs Privately held, phase-focused clinical stage company with lead asset PAT-001 and ongoing Phase 2a results, presenting opportunities for CRO collaborations, clinical trial partnerships, and potential outsourcing for near-term study needs.

Strategic Partnerships History of licensing collaboration with Almirall indicates openness to co-development and licensing deals; potential for new partnerships to expand PAT-001 reach, co-marketing, and region-specific commercialization discussions.

Dermatology Focus Specialization in rare dermatologic diseases creates a niche market; opportunity to position as a target for dermatology-focused contract research, specialty distributors, and patient advocacy channels for trial recruitment and access programs.

Financial Footing Revenue at startup/bootstrapped level with limited headcount; potential for cost-effective vendor engagement, small-team project accelerators, and value-based partnerships that align with capital-efficient development timelines.

Engagement Signals Advisory board addition and public trial milestones indicate active governance and external collaboration; use these touchpoints to propose advisory/consulting roles, patient-centric trial design input, and strategic sponsor alignment discussions.